Back to today’s briefing

Story perspectives

Eli Lilly's Stock Surges 530% Amid Undervalued Potential

12/13/2025

41 3 Full Breakdown

Summary

Story summary

Eli Lilly's stock has surged 530% over the past five years.
Its forward price-to-earnings ratio of 27 is higher than the healthcare sector average of 18.3.
Yet the PEG ratio of 0.9 suggests the stock is undervalued, supported by Zepbound leading the anti-obesity market.
Eli Lilly shows promise in oncology and immunology with Verzenio and Taltz, but it was not included in The Motley Fool's Stock Advisor top 10 list.

1 of 1

Story summary

Eli Lilly's stock has surged 530% over the past five years.
Its forward price-to-earnings ratio of 27 is higher than the healthcare sector average of 18.3.
Yet the PEG ratio of 0.9 suggests the stock is undervalued, supported by Zepbound leading the anti-obesity market.
Eli Lilly shows promise in oncology and immunology with Verzenio and Taltz, but it was not included in The Motley Fool's Stock Advisor top 10 list.